PeptidePedia The community reference

Contributions of INN_Ingrid

User contributions·38 logged edits·page 1 of 1

Contributions by INN_Ingrid, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 15,488 edits includes activity predating the current log.

  1. 11:02, 26 Jul 2026 (diff | hist) Talk:Thermo Fisher Scientific (China) 748 +296 /* Retained certificates: continuity, or a stability claim? */ reply
  2. 12:15, 24 Jul 2026 (diff | hist) Talk:Thermo Fisher Scientific (China) 822 +318 /* Notability, and the retained-certificate claim */ reply
  3. 10:05, 24 Jul 2026 (diff | hist) Talk:Thermo Fisher Scientific (China) 400 +314 /* Notability, and the retained-certificate claim */ new section
  4. 09:10, 22 Jul 2026 (diff | hist) Talk:Asymchem Laboratories 400 +446 /* Notability, and the oldest registry record on the wiki */ new section
  5. 15:43, 13 May 2026 (diff | hist) Tirzepatide 8,037 ±0 move the trade-name history out of the lead and into §Regulatory history
  6. 21:43, 4 May 2026 (diff | hist) Lixisenatide 4,195 ±0 attribute the mechanism claim to the review rather than stating it flatly
  7. 06:32, 5 Apr 2026 (diff | hist) Oral semaglutide 4,582 ±0 m expand §The absorption mechanism
  8. 09:45, 23 Mar 2026 (diff | hist) Talk:International nonproprietary name 400 +153 /* Stem table */ new section
  9. 05:54, 24 Jan 2026 (diff | hist) CagriSema 5,687 ±0 correct the molar mass — source gives the free-base figure, we had the salt
  10. 09:11, 23 Jan 2026 (diff | hist) Talk:Glucagon-like peptide-1 1,233 +155 /* Requested move: → GLP-1 */ reply
  11. 06:11, 23 Jan 2026 (diff | hist) Peptide content 8,404 ±0 state the column chemistry and the gradient the figure was obtained on
  12. 16:12, 20 Jan 2026 (diff | hist) Shenzhen Hybio Pharmaceutical 15,328 +874 m add category for suppliers in China
  13. 22:45, 13 Dec 2025 (diff | hist) Liraglutide 5,967 ±0 m give the INN alongside the trade name at first mention
  14. 06:53, 5 Dec 2025 (diff | hist) Intention-to-treat analysis 4,963 ±0 add the confidence interval to the point estimate
  15. 23:00, 6 Oct 2025 (diff | hist) Placebo-adjusted effect 4,805 ±0 m correct the endpoint hierarchy — that was a secondary endpoint
  16. 17:52, 27 Aug 2025 (diff | hist) Melanotan II 4,374 ±0 m add see also to the closely related analogue
  17. 12:55, 7 Jul 2025 (diff | hist) Survodutide 4,528 +18 m give the INN alongside the trade name at first mention
  18. 21:44, 2 Jun 2025 (diff | hist) Peptide supply chain 7,636 +682 give the vial sizes in millilitres of nominal capacity
  19. 10:44, 26 May 2025 (diff | hist) Sigma-Aldrich (Shanghai) Trading 6,773 +538 correct the other-designations row — those are trading variants, not subsidiaries
  20. 02:07, 13 May 2025 (diff | hist) Repackaging 3,958 ±0 m add the stopper material, since it affects moisture ingress
  21. 20:34, 23 Apr 2025 (diff | hist) Intention-to-treat analysis 3,822 ±0 split the results table so the two doses are separate rows
  22. 14:16, 22 Apr 2025 (diff | hist) Talk:ChinaPeptides 611 +259 /* Which name should the article title use? */ reply
  23. 14:26, 5 Apr 2025 (diff | hist) Trial data comparison 4,023 +806 add the citation for the stability figures taken from the labelling
  24. 13:44, 8 Mar 2025 (diff | hist) Contraindications of incretin therapy 3,570 +162 expand §Scope of this article
  25. 14:38, 9 Feb 2025 (diff | hist) Talk:Chinese Peptide Company 611 +301 /* Requested move: → Chinese Peptide Company Co., Ltd. */ reply
  26. 22:44, 5 Feb 2025 (diff | hist) Cagrilintide 3,147 ±0 rm the equipotency claim — the cited paper does not make it
  27. 05:32, 21 Jan 2025 (diff | hist) Timeline of incretin therapeutics 3,151 +19 m state plainly that the research-use-only form is not approved for human use
  28. 16:03, 13 Jan 2025 (diff | hist) Exenatide 3,419 +30 m expand §The extended-release formulation
  29. 20:16, 8 Jan 2025 (diff | hist) Bacterial endotoxin test 4,102 +123 expand §Methods
  30. 20:03, 4 Jan 2025 (diff | hist) Oral semaglutide 3,241 +28 add the structural figure and caption it properly
  31. 14:10, 8 Nov 2024 (diff | hist) GL Biochem (Shanghai) 7,666 +284 m expand §Notability and coverage
  32. 09:53, 5 Nov 2024 (diff | hist) Beyond-use date 4,264 ±0 fix hyphenation per PP:MOS
  33. 14:37, 8 Oct 2024 (diff | hist) Talk:Nantong Guangyuan Chemical 611 +249 /* Multiple trading names: which is the title? */ reply
  34. 23:45, 26 Sep 2024 (diff | hist) Crude peptide 1,870 ±0 state that a phase-change pack and a gel pack behave differently
  35. 06:20, 12 Sep 2024 (diff | hist) Injection site rotation 2,155 +574 expand §Rotation schemes
  36. 00:01, 11 Sep 2024 (diff | hist) Karl Fischer titration 4,173 +37 state that ultraviolet response is not uniform across impurities
  37. 15:09, 13 Aug 2024 (diff | hist) Dual incretin agonist 2,556 +259 reorder the analogues chronologically rather than alphabetically
  38. 15:16, 24 Jul 2024 (diff | hist) Timeline of incretin therapeutics 1,103 ±0 expand §First-generation drugs